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Anaplastic lymphoma kinase (ALK)–positive lymphomas respond to chemotherapy, 
but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and 
in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who 
were resistant/refractory to cytotoxic therapy. The overall response rate was 10 of 11 
(90.9%; 95% confidence interval [CI] = 58.7% to 99.8%). Disease status at the latest 
follow-up is as follows: four patients are in complete response (CR) (months >21, 
>30, >35, >40) under continuous crizotinib administration; 4 patients had progres-
sion of disease (months 1, 2, 2, 2); 1 patient obtained CR on crizotinib, received an 
allogeneic bone marrow transplant, and is in CR; 2 patients (treated before and/or 
after allogeneic bone marrow transplant) obtained and are still in CR but they have 
stopped crizotinib. Overall and progression-free survival rates at 2 years are 72.7% 
(95% CI = 39.1% to 94.0%) and 63.7% (95% CI = 30.8% to 89.1%), respectively. ALK 
mutations conferring resistance to crizotinib in vitro could be identified in relapsed 
patients. Crizotinib exerted a potent antitumor activity with durable responses in 
advanced, heavily pretreated ALK+ lymphoma patients, with a benign safety profile.
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Anaplastic lymphoma kinase (ALK) 
becomes oncogenic when fused to partner 
genes through chromosomal translocations 
that activate its kinase domain and drive 
the expression of ALK, which is normally 
expressed only in nervous system (1–4). In 
hematological disorders ALK is expressed 
in more than 50% of anaplastic large cell 
lymphomas (ALCLs) as a result of a t(2;5)
(p23;q35) translocation that causes the ALK 
gene to fuse with NPM on chromosome 
5.  ALK-positive large B-cell lymphoma 
(ALK+ DLBCL) is a rare lymphoma with 
a poor prognosis and a frequent t(2;17)
(p23;q23) translocation responsible for 
Clathrin-ALK fusion protein (5).
ALK+ ALCLs respond to cytotoxic 
drugs, but relapses, which bear a poor prog-
nosis, can occur (6–9). Crizotinib is the first 
ALK inhibitor that entered clinical practice; 
it is an orally bioavailable small molecule 
of the ALK and MET receptor tyrosine 
kinases. The activity of crizotinib in ALK+ 
lung cancer is documented (10); no report on 
long-term effects of crizotinib in ALK+ lym-
phomas exists. Impressive short-term thera-
peutic activity was reported in two patients 
(11), but no long-term data are available. 
We report here the long-term follow-up of 
crizotinib administered to 11 patients with 
advanced, resistant, ALK+ lymphomas.
Compassionate use of crizotinib was 
authorized by the institutional review 
boards of our institutions under a named-
patient protocol (see Supplementary 
Materials, available online). Informed con-
sent was signed by each patient. Data were 
collected prospectively, and information on 
centers entering patients was provided by 
Pfizer, the producer of crizotinib. Patients 
were diagnosed with ALK+ non-Hodgkin 
lymphoma by immunohistochemistry and 
fluorescent in situ hybridization using an 
ALK break-apart probe (12). Patients had a 
refractory or relapsed disease after at least 
one prior chemotherapy regimen (typically 
cyclophosphamide, doxorubicin (adria-
mycin), vincristine, prednisone (CHOP); 
see Table  1) and measurable disease. Use 
of cytotoxic drugs/steroids in the 14  days 
before crizotinib administration was not 
permitted (see Supplementary Materials, 
available online). Patients received crizo-
tinib 250 mg twice daily as monotherapy 
until disease progression. Response to 
therapy was assessed according to Response 
Evaluation Criteria In Solid Tumors 
(RECIST) criteria (13).
Kaplan–Meier analysis was conducted 
to assess overall survival (OS) and progres-
sion-free survival (PFS) rates. The analysis 
was conducted accounting for competing 
risk according to Kalleisch–Prentice esti-
mator (14).
Reverse-transcription polymerase chain 
reaction (RT-PCR) for NPM/ALK was per-
formed as described (15). Eleven patients 
(7 men, 4 women; median age = 28 years, 
range = 19–55) were treated. Nine patients 
had an ALCL histology, the remaining 
two had a DLBCL histology. The median 
follow-up for all the patients is 8 months 
(range = 1–40). The median follow-up for 
patients still on crizotinib is 32.5 months 
(range = 21–40). Patients were resistant 
to one to four (median = 3) lines of treat-
ment, including autologous bone marrow 
transplant (n  =  3 patients) and allogeneic 
bone marrow transplant (alloBMT; n  =  2 
patients) (Table 1). All had involvement at 
multiple sites (nodal and extranodal) and an 
Eastern Cooperative Oncology Group per-
formance score of one to four.
The earliest sign of therapeutic activ-
ity detectable by clinical evaluation (symp-
toms, lactate dehydrogenase values) was 
observed within a few days of crizotinib 
(Table  1) (11). The overall response rate 
was 10 of 11 (90.9%; 95% confidence inter-
val [CI]  =  58.7% to 99.8%) and included 
9 complete response (CR) (81.8%; 95% 
CI = 48.2% to 97.8%) and 1 partial remission 
(Table 1). B symptoms disappeared promptly, 
and lactate dehydrogenase levels normalized 
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within 30  days after the start of crizotinib. 
Bone marrow aspirates were NPM/ALK+ by 
fluorescent in situ hybridization analysis in 
four patients and became negative within the 
initial first month of therapy (Supplementary 
Figure 1, available online).
Disease status at the latest follow-
up (October 2013)  is as follows (details 
in Table  1): Four patients (patients 1, 4, 
7, and 11 at months >21, >30, >35, >40, 
respectively) are in CR under continu-
ous crizotinib treatment; they also test 
negative by RT-PCR for NPM/ALK (15). 
Four patients (two with DLBCL [patients 
3 and  5] and two with ALCL [patients 2 
and 6]) progressed (months 1, 2, 2, and 2, 
respectively). Three patients (patients 8, 
9, and 10)  received crizotinib before/after 
alloBMT: one patient obtained CR on cri-
zotinib, received an alloBMT and is in CR; 
two patients (treated before and/or after 
alloBMT) obtained and are still in CR but 
they have stopped crizotinib.
 In the ALCL group, nine of nine patients 
obtained CR (100%; 95% CI = 71.7% to 
100%) with a rate of CR loss of 0.13/year 
(Supplementary Figure 2, available online). 
There were no obvious differences between 
responses and type of cytotoxic drugs used. 
The 2-year PFS and OS rates are 63.7% 
(95% CI  =  30.8% to 89.1%) and 72.7% 
(95% CI = 39.1% to 94.0%), respectively, 
with a plateau in the curve after the initial 
2 months (Figure 1).
Crizotinib-related toxicities observed 
were mild and included ocular flashes 
(n = 10 patients), peripheral edema (n = 3 
patients), skin rash (n = 1 patient), and erec-
tile dysfunction (n = 1 patient). Laboratory 
abnormalities included neutropenia (n = 2 
patients), thrombocytosis (n  =  1 patient), 
and liver function tests elevation (n  =  1 
patient). All toxicities were graded I or II. 
No patient died from a cause related to 
treatment. No treatment-related event led 
to treatment discontinuation.
In two patients (patients 2 and 6), the 
kinase domain of NPM/ALK could be 
amplified from peripheral blood sam-
ples obtained at the time of relapse. 
Deep sequencing of these products (16) 
revealed the presence of ALK mutations 
(17,18).(Supplementary Materials and 
Supplementary Figure 3, available online).
Table 1. Patient characteristics at the time of crizotinib treatment and response rates*
Patient 
No. Age, y Diagnosis
Stage  
(Ann Arbor) ECOG
BM  
involvement, 
%†
Previous  
therapy  
lines
TTN LDH, 
days
TTN fever, 
days
Previous 
BMT
Response,  
duration,  
months
1 26 ALCL IIIB 2 3-->0 CHOP, DHAP, 
HD-VP16
29 2 No CR, >40
2 19 ALCL IVB 3 8-->0 CHOP, DHAP, 
BEAM
22 10 ABMT CR, 2 ‡
3 22 DLBCL IVB 3 65-->0 BFM, HD-CTX, 
HD-AraC, 
Bortezomib
21 Na ABMT PR, 2 ‡
4 22 ALCL IIB 1 0 CHOP, VAD, 
H-CyVAD
30 30 No CR, >35
5 39 DLBCL IVB 3 NA BEP, CHOP, ICE, 
H-CyVAD
19 Na No SD ‡
6 20 ALCL IIB 2 15-->0 CHOP, DHAP, 
BEAM
30 10 ABMT CR, 2
7 47 ALCL IIIBe 2 0 IEV, DHAP, 
CHOP
30 14 No CR, >30
8 28 ALCL IIIB 2 0 CHOP, DHAP, 
mini-BEAM
Na Na No CR, 2
9 34 ALCL IVBe 2 0 CHOP, ESHAP Na 30 No* CR, 3
10 38 ALCL IVB 4 0 CHOP, DHAP, 
VIM
28 15 allogeneic CR, 8
11 55 ALCL IIIB 1 0 CHOP 30 30 No CR, >21
* Patients 1 and 2 correspond to the patients whose short-term course was described in our original report (11). Patient 6 progressed after 2 months of crizotinib. Currently 
the patient is in complete response (CR) on brentuximab vedotin. Patient 8 was treated with crizotinib as a bridge to allogeneic bone marrow transplant (alloBMT). 
The patient obtained a CR and was subsequently transplanted after 2 months of crizotinib; the patient is now in CR with chronic graft versus host disease (GVHD). 
Patient 9 was treated both before alloBMT and after a relapse at day 80 after alloBMT; in both cases a CR was obtained. Crizotinib was discontinued at month 10 
because of patient requests for gastric motility problems considered by the principal investigator (PI) to be related mainly to the transplant procedure; the patient is 
in CR with chronic GVHD. Patient 10 was treated for relapse at day 90 after alloBMT and obtained a CR; crizotinib was discontinued after 8 months because of liver 
function test elevations considered by the PI to be related mainly to the transplant procedure (GVHD); the patient is in CR with chronic GVHD. The different values 
reported in the 6th column, “x –> y”, refer to the percent of positive cells at the two time points. ABMT = autologous bone marrow transplant; BEAM = carmustine, 
etoposide, cytarabine, melphalan; BEP = bleomycin, etoposide, cisplatin; ALCL = anaplastic large cell lymphoma; BFM = 7-drug combination systemic chemotherapy 
plus single-agent intrathecal chemotherapy: prednisone, vincristine daunorubicin, asparaginase, cyclophosphamide, cytarabine, mercaptopurine, plus intrathecal 
methotrexate; BM = bone marrow; BMT = bone marrow transplant; CHOP = cyclophosphamide, doxorubicin (adriamycin), vincristine, prednisone; CR = complete 
response; DHAP = dexamethasone, cisplatin, cytarabine; DLBCL = large B-cell lymphoma; ESHAP = etoposide, methylprednisolone, cytarabine, cisplatin; 
H-CyVAD = alternate regimens of 1) cyclophosphamide, vincristine, doxorubicin (adriamycin), dexamethasone; 2) methotrexate and cytarabine; HD-AraC = high-
dose cytarabine; HD-CTX = high-dose cyclophosphamide; HD-VP16 = high-dose etoposide; ICE = ifosfamide, carboplatin, etoposide; IEV = Ifosfamide, epirubicin, 
etoposide; LDH = lactate dehydrogenase; mini-BEAM: carmustine, etoposide, cytarabine, melphalan; NA = not available; PR = partial remission; PRO = progression 
of disease; SD = stable disease; TTN = time to normalization; VAD = vincristine, doxorubicin, high-dose dexamethasone; VIM = ifosfamide, mitoxantrone, etoposide.
† Evaluated by fluorescent in situ hybridization, using an ALK break apart probe (12), before treatment and after 30 days of crizotinib.
‡ Indicates a death.
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These positive results extend our ini-
tial observation on two patients (patients 
1 and 2)  (11) and provide long-term fol-
low-up data. Crizotinib was well tolerated, 
with objective responses observed within 
30  days after starting treatment in 10 of 
11 patients. Nine patients obtained CR. 
Within 2 months of treatment, four patients 
relapsed, three of whom died shortly after, 
whereas one (patient 6) obtained a durable 
response to brentuximab. The remain-
ing patients showed durable responses 
up to more than 40  months, including 
three patients that were transplanted or 
treated after alloBMT (patients 8, 9, and 
10). Crizotinib showed activity also in 
patients failing alloBMT (patients 9 and 
10), although in this setting the toxicities 
associated with the transplant procedure 
prevented a long-term administration of 
the drug (Table 1).
Previous studies in advanced relapsed 
ALK+ ALCL demonstrated a poor out-
come (6,9), with the exception of brentuxi-
mab-vedotin (19), which showed a 57% CR 
rate (20) and a median PFS of 14.6 months 
(17,18). Although the number of patients 
treated in our study is small, it is noteworthy 
that no patients with previous autologous 
bone marrow transplant showed durable 
responses; this fact could indicate that an 
early treatment with crizotinib after the 
failure of first-line treatment could produce 
better results than when administered later.
In our study, patients in CR also tested 
negative for NPM/ALK when assayed by 
RT-PCR while their pretreatment samples 
were positive. These data further reinforce 
the depth of the response reached and sug-
gest that PCR could represent an effective 
method to follow minimal residual disease 
in adult ALK+ lymphoma, similarly to what 
has been observed in pediatric patients (15). 
A  recent publication described the effects 
of crizotinib on a pediatric population with 
ALK+ tumors, which included 9 patients 
with ALCL (21), with an overall response 
rate of eight of nine patients and a maxi-
mum follow-up of 27  months. Our data 
extend this and our original report (11) 
toward an adult population with a longer 
maximum follow-up (40 vs 27  months). 
In addition, we also showed the activ-
ity of crizotinib in patients who relapsed 
after alloBMT, the potential usefulness of 
a PCR-based assay to monitor MRD, and 
the identification of the molecular nature 
of resistance to crizotinib.
These patients are probably among 
the ones with the longest exposure to cri-
zotinib and are testimony to its long-term 
safety. Although lung cancer patients have 
a median duration of responses of 10 to 
12 months (10), our patients did not show 
further relapses after the first 2  months 
of treatment. In future studies, crizotinib 
could be used in combination with other 
agents to improve the overall response 
rates without exposing patients to long-
term toxicities. It is interesting to note 
that brentuximab and crizotinib seem to be 
non–cross-resistant, as documented by the 
prolonged response to brentuximab after 
the failure of crizotinib in patient 6.
Limitations are present in our study: the 
small number of patients precludes an in-
depth analysis of the relationship between 
factors such as ethnicity or sex and response 
to crizotinib. However, our results were 
substantially confirmed in a recent regis-
tration trial of crizotinib in 15 additional 
ALK+ lymphoma patients (22).
In conclusion, these data indicate that 
ALK+ lymphoma patients have a high 
chance of responding to crizotinib even 
when heavily pretreated, with approxi-
mately half of them not relapsing within 
the first months and then enjoying long-
lasting responses; however, no available 
pretreatment parameter is able to predict 
durable CRs. These data will be useful 
for the management of this aggressive 
disease.
Figure 1. Progression-free survival (PFS) and overall survival curves. 
Gray line shows overall survival and black line shows PFS in ana-
plastic lymphoma kinase (ALK)–positive lymphoma patients treated 
with crizotinib. PFS for patient 8, who was treated before alloge-
neic bone marrow transplant (alloBMT), was censored at the date 
of bone marrow transplant. PFS for patient 9, who was treated both 
before and after alloBMT, was censored at end of the first course 
of crizotinib, before alloBMT. PFS for patient 10, who was treated 
after bone marrow transplant, was censored at the end of crizotinib 
administration.
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